Age-dependent hypertension in Mpv17-deficient mice, a transgenic model of glomerulosclerosis and inner ear disease
Related Experiment Video
Updated: Jul 22, 2026

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis
Published on: June 3, 2018
Abstract:
The mutant mouse strain Mpv17-/-, carries a retroviral germline integration that inactivates the Mpv17 gene. Mpv17-deficient mice develop progressive glomerulosclerosis and sensineural deafness at early age. Characteristic basement membrane alterations are found in both sites of pathology. Mpv17 is a peroxisomal protein involved in the metabolism of reactive oxygen species, yet its molecular function is unknown. Dysregulation of antioxidant enzymes and basal membrane components has been established in this model and successful therapeutic intervention with antioxidants prove the causal role of reactive oxygen species in the development of the disease phenotype. We here investigated if the Mpv17-/- mice might be hypertensive. Indeed, our study revealed that Mpv17-/- mice developed significant systemic hypertension and tachycardia between 4 weeks and 5 months of age, accompanied by polyuria and elevated natriuresis. Judging from serum and urine parameters, the hypertensive condition develops concomitantly with the renal disease. Biochemical and pharmacological studies that used the endothelin receptor antagonist bosentan and the angiotensin converting enzyme inhibitor cilazapril indicated no involvement of the endothelin and renin-angiotensin systems in this hypertension, suggesting a potential novel mechanism of blood pressure regulation in this new murine hypertension model. Thus, Mpv17-/- mice unravel an intriguing new association between a defect in reactive oxygen metabolism and the age-dependent development of hypertension.
Insights
Mpv17-deficient mice exhibit hypertension and tachycardia linked to reactive oxygen metabolism defects. This study identifies a novel association between peroxisomal dysfunction and age-dependent hypertension.
Area of Science:
- Nephrology
- Cardiovascular Research
- Peroxisomal Biology
Background:
- Mpv17-deficient mice (Mpv17-/-) exhibit glomerulosclerosis and deafness due to Mpv17 gene inactivation.
- Mpv17 is a peroxisomal protein implicated in reactive oxygen species (ROS) metabolism, but its function remains unclear.
- Previous studies show ROS contribute to the Mpv17-/- phenotype, with antioxidants proving therapeutic.
Purpose of the Study:
- To investigate the potential development of hypertension in Mpv17-/- mice.
- To explore the underlying mechanisms of hypertension in this model, particularly the involvement of endothelin and renin-angiotensin systems.
Main Methods:
- Systemic blood pressure and heart rate monitoring in Mpv17-/- mice from 4 weeks to 5 months of age.
- Assessment of urine output, natriuresis, and serum parameters.
- Pharmacological studies using endothelin receptor antagonist bosentan and angiotensin-converting enzyme inhibitor cilazapril.
Main Results:
- Mpv17-/- mice developed significant systemic hypertension and tachycardia.
- Hypertension onset coincided with renal disease, characterized by polyuria and elevated natriuresis.
- Endothelin and renin-angiotensin systems were not implicated in the observed hypertension.
Conclusions:
- Mpv17 deficiency leads to a novel form of murine hypertension.
- This hypertension is associated with peroxisomal dysfunction and ROS metabolism defects.
- The findings suggest a new pathway in blood pressure regulation linked to oxidative stress.

